atenolol has been researched along with Tachycardia in 46 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
Tachycardia: Abnormally rapid heartbeat, usually with a HEART RATE above 100 beats per minute for adults. Tachycardia accompanied by disturbance in the cardiac depolarization (cardiac arrhythmia) is called tachyarrhythmia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A double-blind, randomised, controlled trial of forty patients was carried out to determine if oral atenolol pretreatment would reduce the incidence of tachycardia during carotid endarterectomy performed under cervical plexus block." | 9.07 | Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade. ( Cook, RJ; Davies, MJ; Dysart, RH; Scott, DA; Silbert, BS, 1992) |
| "The effect of single oral doses of atenolol (100 mg), metoprolol (100 mg), propranolol (40 mg), and placebo on exercise tachycardia and on heart rate and finger tremor responses to graded injections of isoproterenol was investigated in six normal subjects." | 9.05 | Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects. ( Perucca, E; Pickles, H; Richens, A, 1981) |
| "The effects of atenolol on ventricular arrhythmias were evaluated in 25 men with significant ventricular ectopy." | 9.05 | Reduction of ventricular arrhythmias by atenolol. ( Heng, MK; Zimmer, I, 1985) |
| " The aim was to validate heart rate as a pharmacodynamic endpoint under continuous isoprenaline-induced tachycardia by means of PK-PD modelling of S(-)-atenolol." | 7.74 | Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. ( Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007) |
| " Prior to diagnosis, the patient was treated with a selective beta 1 blocker, atenolol, which resulted in suppression of the dysrhythmia and amelioration of the hypertension." | 7.68 | Pheochromocytoma associated ventricular tachycardia blocked with atenolol. ( Hays, JH; Michaels, RD; O'Brian, JT; Shakir, KM, 1990) |
| " The effect of tachycardia on right atrial pressure (RAP) and dimensions (RAD) and plasma immunoreactive atrial natriuretic factor (IR-ANF) was examined in anaesthetized rabbits before and after the administration of atenolol." | 7.68 | The effect of tachycardia on right atrial dynamics and plasma atrial natriuretic factor in anaesthetized rabbits. ( King, KA; Ledsome, JR, 1990) |
| "5) diagnostic His bundle studies incorporating programmed atrial and ventricular pacing for the induction of tachycardias was performed before and after betablockade with the cardioselective betablocking agent atenolol, in a dose of 5 mg given iv." | 7.66 | Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise. ( Behrenbeck, DW; Braun, V; Gil-Sanchez, D; Hilger, HH; Hombach, V; Höpp, HW; Tauchert, M, 1981) |
| "Exercise tachycardia was monitored for 84 hours after administration of the drugs to monitor beta blockade in vivo." | 6.66 | Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. ( Belz, GG; Butzer, R; Palm, D; Pett, B; Polsak, R; Wellstein, A, 1987) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 5.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| "A double-blind, randomised, controlled trial of forty patients was carried out to determine if oral atenolol pretreatment would reduce the incidence of tachycardia during carotid endarterectomy performed under cervical plexus block." | 5.07 | Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade. ( Cook, RJ; Davies, MJ; Dysart, RH; Scott, DA; Silbert, BS, 1992) |
| "The effect of single oral doses of atenolol (100 mg), metoprolol (100 mg), propranolol (40 mg), and placebo on exercise tachycardia and on heart rate and finger tremor responses to graded injections of isoproterenol was investigated in six normal subjects." | 5.05 | Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects. ( Perucca, E; Pickles, H; Richens, A, 1981) |
| "1 Differences in ability to attenuate isoprenaline tachycardia between the cardioselective beta-adrenoceptor antagonist atenolol and the non-selective drug propranolol, when administered in equivalent anti-exercise tachycardia oral doses, were measured in four normal volunteers." | 5.05 | Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists. ( McGibney, D; Silke, B; Singleton, W; Taylor, SH, 1983) |
| "The effects of atenolol on ventricular arrhythmias were evaluated in 25 men with significant ventricular ectopy." | 5.05 | Reduction of ventricular arrhythmias by atenolol. ( Heng, MK; Zimmer, I, 1985) |
| "The comparative potency of two beta-blockers, propranolol and atenolol, in the inhibition of exercise tachycardia and isoproterenol-tachycardia has been studied in two groups of hypertensive patients, using oral doses which were increased weekly." | 5.04 | Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man. ( Amery, A; De Plaen, JF; Reybrouck, T, 1976) |
| " The aim was to validate heart rate as a pharmacodynamic endpoint under continuous isoprenaline-induced tachycardia by means of PK-PD modelling of S(-)-atenolol." | 3.74 | Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint. ( Danhof, M; de Lange, EC; Freijer, J; van Steeg, TJ, 2007) |
| "Our aim was primarily to assess whether or not a vagal tachycardia can be elicited in vivo without administration of atropine, and secondly to evaluate whether the dose of atropine, a muscarinic antagonist, determines the magnitude of the tachycardia." | 3.73 | An investigation into the physiological relevance of the vagal tachycardia in the anaesthetized dog. ( Markos, F; Snow, HM, 2006) |
| " Increasing doses (25 pmol - 1 nmol) of selective agonists at NK(1) ([Sar(9),Met(O(2))(11)]SP), NK(2) ([beta-Ala(8)]NKA(4 - 10)) and NK(3) (senktide) receptors into the SN produced tachycardia which was selectively and reversibly blocked by the prior injection of tachykinin antagonists at NK(1) (RP67580, 250 pmol), NK(2) (SR48968, 250 pmol) and NK(3) (R-820, 500 pmol) receptor." | 3.71 | Modulation of cardiac activity by tachykinins in the rat substantia nigra. ( Couture, R; Lessard, A, 2001) |
| " Atenolol neither modified HR nor BP variability in rats with hyperthyroidism." | 3.70 | Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism. ( Elghozi, JL; Laude, D; Ponchon, P; Safa-Tisseront, V, 1998) |
| "This study demonstrates that the tachycardia produced by systemic injections of the beta-adrenoceptor agonist, isoproterenol (10 microg/kg, i." | 3.70 | In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors. ( Lewis, SJ; Whalen, EJ, 1999) |
| " Prior to diagnosis, the patient was treated with a selective beta 1 blocker, atenolol, which resulted in suppression of the dysrhythmia and amelioration of the hypertension." | 3.68 | Pheochromocytoma associated ventricular tachycardia blocked with atenolol. ( Hays, JH; Michaels, RD; O'Brian, JT; Shakir, KM, 1990) |
| " The effect of tachycardia on right atrial pressure (RAP) and dimensions (RAD) and plasma immunoreactive atrial natriuretic factor (IR-ANF) was examined in anaesthetized rabbits before and after the administration of atenolol." | 3.68 | The effect of tachycardia on right atrial dynamics and plasma atrial natriuretic factor in anaesthetized rabbits. ( King, KA; Ledsome, JR, 1990) |
| "Intoxication with metaproterenol, a mainly beta-2 selective agonist, was diagnosed in a dog with tachycardia, tachypnea, weakness, vomiting, and a history of exposure to the drug." | 3.68 | Metaproterenol intoxication in a dog. ( Keene, BW; Rush, JE, 1990) |
| "5) diagnostic His bundle studies incorporating programmed atrial and ventricular pacing for the induction of tachycardias was performed before and after betablockade with the cardioselective betablocking agent atenolol, in a dose of 5 mg given iv." | 3.66 | Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise. ( Behrenbeck, DW; Braun, V; Gil-Sanchez, D; Hilger, HH; Hombach, V; Höpp, HW; Tauchert, M, 1981) |
| " Beta-blocker use at the 2 dosage levels was associated with significant improvement in survival compared with the nonuse of beta blockers (hazard ratios 0." | 2.71 | Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II). ( Andrews, M; Brodine, WN; Daubert, JP; Hall, WJ; Hockstad, ES; Lee, JK; McNitt, S; Moss, AJ; Tung, RT; Zareba, W, 2005) |
| "Exercise tachycardia was monitored for 84 hours after administration of the drugs to monitor beta blockade in vivo." | 2.66 | Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy. ( Belz, GG; Butzer, R; Palm, D; Pett, B; Polsak, R; Wellstein, A, 1987) |
| "Atenolol was discontinued because of adverse effects in 12 patients." | 2.66 | Atenolol for ventricular ectopy: a dose-response study. ( Fenster, PE; Goldman, S; Horwitz, LD; Lazzara, R; Marcus, FI; Morrison, D; Reynolds, D; Serokman, R; Thadani, U, 1987) |
| " We previously demonstrated that Ang II combined with evolving cardiodepression (48-hour tachycardia pacing, 48hP) induces marked chamber stiffening and increases metalloproteinases (MMPs)." | 1.31 | beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction. ( Crow, MT; Gluzband, YA; Janicki, JS; Kass, DA; Lindsey, ML; Paolocci, N; Senzaki, H, 2000) |
| "Isoflurane caused an increase in HR at 0." | 1.29 | Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits. ( Grigioni, M; Marano, G; Tiburzi, F; Vergari, A; Zanghi, F, 1996) |
| "73 patients (89%) had ventricular extrasystoles in the 24 hour ambulatory ECG, 33 (40%) of them with an average of more than 30/h." | 1.27 | [Prevalence, therapeutic modification and prognostic significance of ventricular arrhythmias in the mitral valve prolapse syndrome]. ( Kafka, W, 1985) |
| "Ischemia-induced arrhythmias were studied during a 30 min period of occlusion of the left anterior descending (LAD) coronary artery, and 100% of control animals (n = 24) exhibited ventricular tachycardia and 63% ventricular fibrillation." | 1.27 | Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol. ( Braimbridge, MV; Hearse, DJ; Kinoshita, K; Manning, AS, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 17 (36.96) | 18.7374 |
| 1990's | 11 (23.91) | 18.2507 |
| 2000's | 15 (32.61) | 29.6817 |
| 2010's | 3 (6.52) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fassini, A | 1 |
| Resstel, LB | 2 |
| Corrêa, FM | 2 |
| Selen, DJ | 1 |
| Gilbert, MP | 1 |
| Kurnik, D | 2 |
| Li, C | 2 |
| Sofowora, GG | 2 |
| Friedman, EA | 2 |
| Muszkat, M | 2 |
| Xie, HG | 1 |
| Harris, PA | 1 |
| Williams, SM | 1 |
| Nair, UB | 1 |
| Wood, AJ | 2 |
| Stein, CM | 2 |
| Gopinathannair, R | 1 |
| Sullivan, RM | 1 |
| Olshansky, B | 1 |
| Cunningham, AJ | 1 |
| Kohli, U | 1 |
| Menon, UB | 1 |
| Palatini, P | 1 |
| Good, L | 1 |
| Côté, E | 1 |
| Wright, KN | 1 |
| Brodine, WN | 1 |
| Tung, RT | 1 |
| Lee, JK | 1 |
| Hockstad, ES | 1 |
| Moss, AJ | 1 |
| Zareba, W | 1 |
| Hall, WJ | 1 |
| Andrews, M | 1 |
| McNitt, S | 1 |
| Daubert, JP | 1 |
| Hogan, K | 1 |
| Markos, F | 3 |
| Snow, HM | 2 |
| van Steeg, TJ | 1 |
| Freijer, J | 1 |
| Danhof, M | 1 |
| de Lange, EC | 1 |
| Ngampramuan, S | 1 |
| Baumert, M | 1 |
| Beig, MI | 1 |
| Kotchabhakdi, N | 1 |
| Nalivaiko, E | 1 |
| Gould, S | 1 |
| Westwood, FR | 1 |
| Curwen, JO | 1 |
| Ashton, SE | 1 |
| Roberts, DW | 1 |
| Lovick, SC | 1 |
| Ryan, AJ | 1 |
| Ajala, AM | 1 |
| Goodwin, JA | 1 |
| Goodwin, SR | 1 |
| Josephson, GD | 1 |
| Laakso, M | 1 |
| Pentikäinen, PJ | 1 |
| Pyörälä, K | 1 |
| Neuvonen, PJ | 1 |
| Perucca, E | 1 |
| Pickles, H | 1 |
| Richens, A | 1 |
| McGibney, D | 1 |
| Singleton, W | 1 |
| Silke, B | 1 |
| Taylor, SH | 1 |
| Montenero, AS | 1 |
| Frustaci, A | 1 |
| Gianolla, F | 1 |
| Pennestri, F | 1 |
| Santarelli, P | 1 |
| Bellocci, F | 1 |
| Rasmussen, K | 1 |
| Andersen, K | 1 |
| Wang, H | 1 |
| Hombach, V | 1 |
| Braun, V | 1 |
| Höpp, HW | 1 |
| Gil-Sanchez, D | 1 |
| Behrenbeck, DW | 1 |
| Tauchert, M | 1 |
| Hilger, HH | 1 |
| Steyer, M | 1 |
| Poleska, W | 1 |
| Diemer, HP | 1 |
| Schmidt, H | 1 |
| Heidenreich, J | 1 |
| Kumagai, K | 1 |
| Suzuki, H | 1 |
| Ichikawa, M | 1 |
| Jimbo, M | 1 |
| Nishizawa, M | 1 |
| Ryuzaki, M | 1 |
| Saruta, T | 1 |
| Marano, G | 1 |
| Grigioni, M | 1 |
| Tiburzi, F | 1 |
| Vergari, A | 1 |
| Zanghi, F | 1 |
| Grubb, BP | 1 |
| Kosinski, DJ | 1 |
| Boehm, K | 1 |
| Kip, K | 1 |
| Safa-Tisseront, V | 1 |
| Ponchon, P | 1 |
| Laude, D | 1 |
| Elghozi, JL | 1 |
| Kuznetsov, AS | 1 |
| Orme, S | 1 |
| Channer, KS | 1 |
| Whalen, EJ | 1 |
| Lewis, SJ | 1 |
| Senzaki, H | 1 |
| Paolocci, N | 1 |
| Gluzband, YA | 1 |
| Lindsey, ML | 1 |
| Janicki, JS | 1 |
| Crow, MT | 1 |
| Kass, DA | 1 |
| Lessard, A | 1 |
| Couture, R | 1 |
| Schley, G | 2 |
| Beckmann, R | 1 |
| Hengstebeck, W | 1 |
| De Plaen, JF | 1 |
| Amery, A | 1 |
| Reybrouck, T | 1 |
| Abendroth, RR | 1 |
| Meesmann, W | 1 |
| Stephan, K | 1 |
| Hübner, H | 1 |
| Davies, MJ | 1 |
| Dysart, RH | 1 |
| Silbert, BS | 1 |
| Scott, DA | 1 |
| Cook, RJ | 1 |
| Michaels, RD | 1 |
| Hays, JH | 1 |
| O'Brian, JT | 1 |
| Shakir, KM | 1 |
| King, KA | 1 |
| Ledsome, JR | 2 |
| Rush, JE | 1 |
| Keene, BW | 1 |
| Kafka, W | 1 |
| Rankin, AJ | 1 |
| Courneya, CA | 1 |
| Wilson, N | 1 |
| Wellstein, A | 1 |
| Palm, D | 1 |
| Belz, GG | 1 |
| Butzer, R | 1 |
| Polsak, R | 1 |
| Pett, B | 1 |
| Uprichard, AC | 1 |
| Harron, DW | 1 |
| Kinoshita, K | 1 |
| Hearse, DJ | 1 |
| Braimbridge, MV | 1 |
| Manning, AS | 1 |
| Fenster, PE | 1 |
| Reynolds, D | 1 |
| Horwitz, LD | 1 |
| Morrison, D | 1 |
| Goldman, S | 1 |
| Thadani, U | 1 |
| Lazzara, R | 1 |
| Serokman, R | 1 |
| Marcus, FI | 1 |
| Heng, MK | 1 |
| Zimmer, I | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Genetic Determinants of Response to Beta Blockade[NCT00837902] | 154 participants (Actual) | Interventional | 2009-01-31 | Completed | |||
| Essential Arterial Hypotension and Allostasis Registry[NCT02018497] | 5,000 participants (Anticipated) | Observational [Patient Registry] | 1995-01-31 | Recruiting | |||
| A Double-Blinded, Placebo-Controlled Study To Assess Hemodynamic Changes, Orthostatic Tolerance, Out-Patient Fatigue And Quality Of Life In Neuropathic And Non-Neuropathic POTS Patients In Response To Adrenoreceptor Agonist And Antagonist[NCT03070730] | Phase 1/Phase 2 | 8 participants (Actual) | Interventional | 2011-08-15 | Terminated (stopped due to Recruitment was slow and subjects declined participation after signing the ICF.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Reduction in heart rate based upon genotype while exercising. Participants exercised on a recumbent bike for 2 minutes at 25W, 2 minutes at 50W, and 2 minutes at 75W twice, once before taking atenolol, and once 2.5 hours after oral administration of 25 mg of atenolol. Data points represent unadjusted mean reduction in heart rate in the 3 genotype groups. (NCT00837902)
Timeframe: 2 exercise periods of 6 minutes each. 6 minutes of exercise before taking atenolol, and 6 minutes of exercise starting 2.5 hours after taking 25 mg of atenolol (2.5 hours + 6 minutes)
| Intervention | beats per minute (Mean) | |||
|---|---|---|---|---|
| 0, baseline | 2 minutes from baseline, 2 minutes exercise at 25W | 4 minutes from baseline, 2 minutes exercise at 50W | 6 minutes from baseline, 2 minutes exercise at 75W | |
| GLN/GLN | 7.9 | 9.6 | 11.7 | 14 |
| GLN/LEU | 6 | 8.4 | 10.9 | 12.4 |
| LEU/LEU | 3.3 | 7.4 | 9.1 | 10 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: 2 weeks after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
A 14 item self-report questionnaire. Subjects respond on a continuum of 1 to 4 questions evaluating fatigue intensity while distinguishing physical from mental fatigue. (NCT03070730)
Timeframe: up to 3 days after randomization
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: Up to 3 days after randomization
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
"Measures of follow up testing will be the scores on the physical functioning subscale of the 7 item patient global impression of change with items anchored by :very much better to very much worse." (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Hospital Anxiety and Depression Scales. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Checklist Individual Strength (CIS). (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the EuroQOL. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Fatigue Severity Scale. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Multidimensional Fatigue Inventory (MFI). (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the Orthostatic Intolerance Questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Measures of follow up testing will be the scores on the physical functioning subscale of the SF-36 questionnaire. (NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
(NCT03070730)
Timeframe: 1 week after third intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after first intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
Maximal postural tachycardia is the maximum heart rate during a 20-min tilt table test. (NCT03070730)
Timeframe: 2 weeks after second intervention
| Intervention | () |
|---|---|
| Atenolol | 0 |
| Placebos | 0 |
| Droxidopa | 0 |
8 trials available for atenolol and Tachycardia
| Article | Year |
|---|---|
Effects of beta-blockers on implantable cardioverter defibrillator therapy and survival in the patients with ischemic cardiomyopathy (from the Multicenter Automatic Defibrillator Implantation Trial-II).
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Carbazoles; Carvedilol; Defibrillators, Implantable; Fe | 2005 |
Effect of atenolol, metoprolol, and propranolol on isoproterenol-induced tremor and tachycardia in normal subjects.
Topics: Adult; Atenolol; Blood Pressure; Heart Rate; Humans; Male; Metoprolol; Physical Exertion; Propanolam | 1981 |
Observations on the mechanism underlying the differences in exercise and isoprenaline tachycardia after cardioselective and non-selective beta-adrenoceptor antagonists.
Topics: Adult; Atenolol; Heart Rate; Humans; Isoproterenol; Male; Middle Aged; Physical Exertion; Propanolam | 1983 |
Comparative potency of atenolol and propranolol as beta-adrenergic blocking agents in man.
Topics: Adult; Atenolol; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Evaluation; Female | 1976 |
Prevention of tachycardia with atenolol pretreatment for carotid endarterectomy under cervical plexus blockade.
Topics: Aged; Atenolol; Bradycardia; Cervical Plexus; Creatine Kinase; Double-Blind Method; Electrocardiogra | 1992 |
Reduction of exercise tachycardia in man after propranolol, atenolol and bisoprolol in comparison to beta-adrenoceptor occupancy.
Topics: Adrenergic beta-Antagonists; Adult; Atenolol; Bisoprolol; Double-Blind Method; Exercise Test; Heart | 1987 |
Atenolol for ventricular ectopy: a dose-response study.
Topics: Adult; Aged; Ambulatory Care; Arrhythmias, Cardiac; Atenolol; Circadian Rhythm; Dose-Response Relati | 1987 |
Reduction of ventricular arrhythmias by atenolol.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Heart Ventricles; Humans; Male; Middle Aged; Tachycardi | 1985 |
38 other studies available for atenolol and Tachycardia
| Article | Year |
|---|---|
Prelimbic cortex GABA
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Bicuculline; Blood Pressure; GABA Antagonists; Limbi | 2016 |
Nausea/vomiting · tachycardia · unintentional weight loss · Dx?
Topics: Adult; Antithyroid Agents; Atenolol; Female; Humans; Hyperthyroidism; Methimazole; Nausea; Pulmonary | 2017 |
Beta-1-adrenoceptor genetic variants and ethnicity independently affect response to beta-blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Atenolol; Black People; | 2008 |
Slower heart rates for healthy hearts: time to redefine tachycardia?
Topics: Adrenergic beta-Antagonists; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Ateno | 2008 |
GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Adult; Alleles; Atenolol; Black | 2009 |
Elevated heart rate in hypertension: a target for treatment?
Topics: Anti-Arrhythmia Agents; Atenolol; Heart Rate; Humans; Hypertension; Tachycardia; Treatment Outcome | 2010 |
ECG of the month. Narrow-complex monomorphic tachycardia with a ventricular rate of 320 beats/min.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Atrial Fibrillation; Diagnosis, Differential; Digoxin; Do | 2002 |
Pressor and tachycardic responses evoked by microinjections of L-glutamate into the medial prefrontal cortex of unanaesthetized rats.
Topics: Animals; Antihypertensive Agents; Atenolol; Blood Pressure; Corpus Callosum; Glutamic Acid; Gyrus Ci | 2005 |
An investigation into the presence of a vagal tachycardia and the effect of vasoactive intestinal polypeptide on rat heart rate in vitro.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Atropine; Dose-Response Relationship, Drug; Electric Stim | 2006 |
An investigation into the physiological relevance of the vagal tachycardia in the anaesthetized dog.
Topics: Animals; Atenolol; Atropine; Blood Pressure; Dogs; Dose-Response Relationship, Drug; Electric Stimul | 2006 |
Vagal postganglionic origin of vasoactive intestinal polypeptide (VIP) mediating the vagal tachycardia.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Blood Pressure; Cardiac Catheterization; Coronary Ve | 2006 |
Pharmacokinetic-pharmacodynamic modelling of S(-)-atenolol in rats: reduction of isoprenaline-induced tachycardia as a continuous pharmacodynamic endpoint.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Algorithms; Animals; Atenolol; Dose-Response | 2007 |
Activation of 5-HT(1A) receptors attenuates tachycardia induced by restraint stress in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Atenolol; Dose-Response Relationship, Drug; Heart R | 2008 |
Effect of pretreatment with atenolol and nifedipine on ZD6126-induced cardiac toxicity in rats.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Antineoplasti | 2007 |
Undiagnosed Graves' Disease contributing to sleep disordered breathing in a child undergoing adenotonsillectomy.
Topics: Acetaminophen; Adenoidectomy; Adenoids; Analgesics, Non-Narcotic; Analgesics, Opioid; Antihypertensi | 2008 |
Prolongation of the Q-T interval caused by sotalol--possible association with ventricular tachyarrhythmias.
Topics: Adrenergic beta-Antagonists; Atenolol; Electrocardiography; Heart Ventricles; Humans; Kinetics; Male | 1981 |
[Clinical, electrophysiologic and histologic findings in a case of substained idiopathic ventricular tachycardia].
Topics: Adult; Atenolol; Biopsy; Electrocardiography; Heart Ventricles; Humans; Male; Myocardium; Tachycardi | 1982 |
Atrial fibrillation induced by atenolol.
Topics: Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Electrocardiography; Female; Human | 1982 |
Antiarrhythmic effects of acute betablockade with atenolol on supraventricular tachycardias at rest and during exercise.
Topics: Adult; Aged; Anti-Arrhythmia Agents; Atenolol; Cardiac Pacing, Artificial; Electric Stimulation; Ele | 1981 |
Combined use of beta-sympathomimetic drugs and beta-blockers during labour.
Topics: Atenolol; Blood Pressure; Ethanolamines; Female; Fenoterol; Heart Rate; Humans; Metoprolol; Obstetri | 1981 |
Comparison of early and late start of antihypertensive agents and baroreceptor reflexes.
Topics: Aging; Animals; Antihypertensive Agents; Atenolol; Baroreflex; Blood Pressure; Enalapril; Heart Rate | 1996 |
Effects of isoflurane on cardiovascular system and sympathovagal balance in New Zealand white rabbits.
Topics: Anesthetics, Inhalation; Animals; Atenolol; Baroreflex; Blood Pressure; Cardiovascular Physiological | 1996 |
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans; | 1997 |
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans; | 1997 |
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans; | 1997 |
The postural orthostatic tachycardia syndrome: a neurocardiogenic variant identified during head-up tilt table testing.
Topics: Adult; Atenolol; Autonomic Nervous System Diseases; Erythropoietin; Female; Fludrocortisone; Humans; | 1997 |
Autonomic contribution to the blood pressure and heart rate variability changes in early experimental hyperthyroidism.
Topics: Animals; Atenolol; Atropine; Autonomic Nervous System; Blood Pressure; Cardiomegaly; Disease Models, | 1998 |
[The treatment of tachy-systolic fibrillation in a patient after aortocoronary shunting].
Topics: Anti-Arrhythmia Agents; Arteriovenous Shunt, Surgical; Atenolol; Atrial Fibrillation; Humans; Male; | 1999 |
Tachycardia following low-tension electrocution.
Topics: Adenosine; Adult; Anti-Arrhythmia Agents; Atenolol; Atrioventricular Node; Electric Injuries; Electr | 1999 |
In vivo evidence that isoproterenol may increase heart rate in the rat by mechanisms in addition to activation of cardiac beta(1)- or beta(2)-adrenoceptors.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Atenolol; Biological Clocks; Drug In | 1999 |
beta-blockade prevents sustained metalloproteinase activation and diastolic stiffening induced by angiotensin II combined with evolving cardiac dysfunction.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensin II; Animals; Atenolol; Diastole; | 2000 |
Modulation of cardiac activity by tachykinins in the rat substantia nigra.
Topics: Adrenergic beta-Antagonists; Animals; Atenolol; Atropine; Benzamides; Blood Pressure; Hemodynamics; | 2001 |
[The treatment of acute cardiac dysrhythmias with atenolol (Tenormin) particularly after myocardial infarction (author's transl)].
Topics: Acute Disease; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Atrial Fibrillation; Atrial Flutter; Car | 1978 |
[Effects of the beta-blocking agent atenolol on arrhythmias especially ventricular fibrillation and fibrillation threshold after acute experimental coronary artery occlusion (author's transl)].
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Carotid Arteries; Coronary Disease; Coronary Vessels; Dogs; | 1977 |
Pheochromocytoma associated ventricular tachycardia blocked with atenolol.
Topics: Adrenal Gland Neoplasms; Adult; Atenolol; Dopamine; Electrocardiography; Epinephrine; Humans; Hypert | 1990 |
The effect of tachycardia on right atrial dynamics and plasma atrial natriuretic factor in anaesthetized rabbits.
Topics: Anesthesia, Intravenous; Animals; Atenolol; Atrial Natriuretic Factor; Blood Pressure; Heart; Heart | 1990 |
Metaproterenol intoxication in a dog.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Dog Diseases; Dogs; Echocardiography; Electrocardiography; | 1990 |
[Prevalence, therapeutic modification and prognostic significance of ventricular arrhythmias in the mitral valve prolapse syndrome].
Topics: Adolescent; Adult; Aged; Arrhythmias, Cardiac; Atenolol; Cardiac Complexes, Premature; Electrocardio | 1985 |
Tachycardia releases atrial natriuretic peptide in the anesthetized rabbit.
Topics: Acetylcholine; Animals; Atenolol; Atrial Natriuretic Factor; Atropine; Blood Pressure; Cardiac Pacin | 1986 |
Atenolol, but not mexiletine, protects against stimulus-induced ventricular tachycardia in a chronic canine model.
Topics: Animals; Anti-Arrhythmia Agents; Atenolol; Blood Pressure; Coronary Circulation; Disease Models, Ani | 1989 |
Ischemia- and reperfusion-induced arrhythmias in conscious rats--studies with prazosin and atenolol.
Topics: Animals; Arrhythmias, Cardiac; Atenolol; Blood Pressure; Coronary Disease; Heart Rate; Male; Myocard | 1988 |